Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$102.28 USD

102.28
1,345,864

-2.40 (-2.29%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

Why Zimmer (ZBH) Could Beat Earnings Estimates Again

by Zacks Equity Research

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.

Alcon (ALC) Gains From Robust Contact Lense Sales, Launches

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Align Technology's (ALGN) New Pacts, Innovation Aid Growth

by Zacks Equity Research

Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.

Labcorp (LH) Completes Strategic Deal With Jefferson Health

by Zacks Equity Research

Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Quest Diagnostics (DGX) Brings New Test for Prostate Cancer

by Zacks Equity Research

Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.

Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health

by Zacks Equity Research

Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

by Zacks Equity Research

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Penumbra (PEN) Gains on New Launches Amid Currency Headwind

by Zacks Equity Research

Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.

Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes

by Zacks Equity Research

Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.

Sensus Healthcare (SRTS) Expands Global Base With New Pact

by Zacks Equity Research

The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.

Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023

by Zacks Equity Research

Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.

Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD

by Zacks Equity Research

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.

Thermo Fisher (TMO) Announces the Acquisition of CorEvitas

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

by Zacks Equity Research

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

by Zacks Equity Research

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.